<DOC>
	<DOCNO>NCT01989949</DOCNO>
	<brief_summary>This phase 1 , open-label , randomize pharmacokinetic safety study healthy adult subject , undergo bronchoscopy bronchoalveolar lavage ( BAL ) receive seven ( 7 ) dose 1.0 mg/kg IV TP-434 .</brief_summary>
	<brief_title>Safety Pharmacokinetic ( PK ) Study Assess Bronchopulmonary Disposition IV Eravacycline ( TP-434 ) Healthy Men Women</brief_title>
	<detailed_description>This phase 1 , open-label , randomize pharmacokinetic safety study healthy adult subject , undergo bronchoscopy bronchoalveolar lavage ( BAL ) receive seven ( 7 ) dose 1.0 mg/kg IV TP-434 . Dosing twice daily ( q12h ) three consecutive day begin day one ( 1 ) morning dose day four ( 4 ) . Approximately 20 subject enrol study one ( 1 ) investigational site . The population study healthy male female subject 18 65 year age . This study include Screening Period 30 day , 4 day , open-label Treatment Period , two week Follow-up Period . There one 6 day/5 night inpatient stay ( Days -1 5 ) Treatment Period one outpatient visit end Follow-up Period . Excluding Screening Period , total duration confinement ( Clinical Research Center ) approximately six ( 6 ) day total study duration , include screening , approximately three ( 3 ) week . Participants admit Clinical Research Center Day -1 . Participants receive four ( 4 ) day intravenous TP-434 1.0 mg/kg body weight twice daily ( q12h ) three consecutive day morning dose day four ( 4 ) ( total 7 dos ) start Day 1 . Blood urine sample , ECGs , vital sign collect safety analysis specify time point . Pharmacokinetic blood sample occur Day 4before Day 4 dose TP-434 specify time point . Participants randomize single BAL procedure time point . Bronchoscopy BAL perform follow time point dose TP-434 Day 4 : two ( 2 ) , four ( 4 ) , six ( 6 ) , 12 hour start infusion . Bronchoscopy BAL conduct five ( 5 ) different participant time point . Each subject undergo bronchoscopy BAL .</detailed_description>
	<criteria>1 . Healthy male nonpregnant , nonlactating healthy female 2 . Age &gt; 18 ≤ 65 year age , inclusive 3 . Body mass index 18 33 kg/m2 , outside range , consider clinically significant Investigator 4 . Must willing able communicate participate whole study 5 . Must provide write informed consent 6 . Must agree use adequate method contraception 1 . Participation clinical research study within previous 3 month 2 . Subjects previously receive TP434 3 . History drug alcohol abuse past 2 year 4 . Regular alcohol consumption male &gt; 21 unit per week female &gt; 14 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) 5 . Current smoker smoke within last 6 month . 6 . Subjects suitable vein multiple venepunctures/cannulation assess Investigator screen 7 . Clinically significant abnormal biochemistry , haematology , coagulation urinalysis judge Investigator 8 . Positive test drug abuse 9 . Positive hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ; I II ) result 10 . History chronic respiratory disorder judge Investigator 11 . Serious adverse reaction serious hypersensitivity tetracycline , midazolam like compound , lidocaine like compound , formulation excipients 12 . Donation loss great 400 mL blood within previous 3 month 13 . Subjects take , take , prescribed overthecounter drug herbal remedy ( exception anti inflammatory , antihypertensive medication , hormone replacement therapy ) 14 day Investigational Medicinal Product administration unless judge interfere study objective accord Investigator sponsor 's medical monitor 14 . Failure satisfy Investigator fitness participate reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>